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Abstract: Chronic allograft nephropathy (CAN) is the leading cause of late allograft loss after 
renal transplantation (RT), which continues to remain an unresolved problem. A rat model of 
CAN was first described in 1969 by White et al. Although the rat model of RT can be techni-
cally challenging, it is attractive because the pathogenesis of CAN is similar to that following 
human RT and the pathological features of CAN develop within months as compared with years 
in human RT. The rat model of RT is considered as a useful investigational tool in the field of 
experimental transplantation research. We have reviewed the literature on studies of rat RT 
reporting the donor and recipient strain combinations that have investigated resultant survival 
and histological outcomes. Several different combinations of inbred and outbred rat combina-
tions have been reported to investigate the multiple aspects of transplantation, including acute 
rejection, cellular and humoral rejection mechanisms and their treatments, CAN, and potential 
targets for its prevention.
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Introduction
Despite the advances in immunosuppressive agents, chronic allograft nephropathy 
(CAN) remains the leading cause of late allograft loss following renal transplantation 
(RT).1 Experimental research has been undertaken in animal models to understand 
the pathogenesis and molecular biology of CAN and to identify potential therapeutic 
targets for its prevention and treatment.2,3
In humans, CAN develops slowly over months and years before being fully 
established. In rat models of CAN, impairment of renal function and histopathol-
ogy similar to that described in humans can be produced in a few months, allowing 
investigators to study its pathology within a reasonable period of time. The factors 
implicated in the pathogenesis of CAN in the rat mimic the pathogenesis of CAN in 
human clinical RT; particularly to RT from a live kidney donor source, since the cold-
ischemia time is short in both situations. Thus, the rat provides an important model of 
RT in which to study the pathology and potential treatment of CAN.4 The aim of this 
paper is to review the published literature on the models of CAN and to explore their 
advantages and disadvantages and the interventions undertaken.
Literature search
The literature search was carried out in PubMed and relevant websites using the 
words “renal transplantation”, “chronic allograft nephropathy”, “rat”, “animals”, 
“transplant fibrosis”, and “prevention”. Relevant references were compiled in the 
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EndNote (X6.0.1, Bld 6599; Thomson Reuters, New York, 
NY, USA) software.
Advantages of rat models
RT techniques have been described in pigs, dogs, rab-
bits, rats, and mice.5–9 Compared with larger animals, the 
advantages of using the rat include 1) improved long-
term survival of renal transplants due to the use of inbred 
strains, 2) lower cost of experimental animals, 3) simple 
animal maintenance which does not require sophisticated 
facilities, 4) less critical requirement for aseptic surgery, 
and 5) well established techniques of vascular and ureteric 
anastomoses for RT.10,11
Strains of rats
The first description of RT in rats was presented by Bernard 
Fisher and Sun Lee at the American College of Surgeons 
Meeting in Chicago in 1961 and subsequently published in 
1965.8,12 RT was performed using inbred Lewis (LEW) rats, 
and therefore no immunosuppressive regimens were required. 
In subsequent studies, the following rat strains were used as 
either donor or recipient: Fisher 344 (inbred (In)), Sprague 
Dawley (SD) (outbred (Ou)), Wistar Furth (WF) (outbred 
(Ou)), LEW (inbred (In)), brown Norway (BN) (inbred (In)), 
and Dark Agouti (DA) (inbred (In)). Either inbred or outbred 
strains may be used depending upon the aim of the individual 
study.10,13–23
The following combinations such as Fisher 344-to-
LEW, DA-to-BN, DA-to-WF, DA-to-LEW, SD-to-WF, and 
LEW to-BN have been used to induce CAN, with both advan-
tages and disadvantages to each model.23–33 However, since 
the Fisher 344-to-LEW model of RT is the most commonly 
employed in experimental studies, the establishment and 
application of this combination is described in detail.
Fisher 344-to-LEW model of CAN
establishment of the model
White and Mullen34 described in 1969 for the first time RT 
using the Fisher 344 (F344) rat as donor and the LEW rat as 
recipient to produce a model of chronic rejection. Although 
the LEW-to-LEW isograft maintains relatively well  preserved 
renal  function, F344 allografts develop clinical and histo-
pathological features of CAN within a few weeks to months 
after RT.35 Paul et al39 demonstrated that RT between F344-
to-LEW rats survives spontaneously, without the use of 
immunosuppressive drugs. The F344-to-LEW model is useful 
because the rat strains differ partially at major histocompat-
ibility complex (MHC) (class I and class II) and various 
non-MHC loci, thereby making a weakly histocompatible 
combination that allows RT without immunosuppression, 
which cannot be done in humans. LEW rats receiving an 
F344 graft develop raised glomerular pressure and protei-
nuria after 1 week post-RT, which gradually evolves into 
CAN.36 The histological changes occur  predominantly in the 
glomeruli showing mesangial expansion, glomerular fibrosis, 
intimal thickening of blood vessels, dilatation of capillar-
ies, splitting of capillary  basement membrane, and deposi-
tion of  eosinophilic materials in  capillary loops.  Classical 
changes of CAN in the vascular and tubulointerstitium 
occur simultaneously or later, but similar to lesions seen in 
human RT.12 Vass et al37 observed marked increase in the 
number of perivascular and interstitial lymphatic vessels in 
the allografts, which correlated with the extent of interstitial 
fibrosis.
The same investigators also demonstrated that LEW 
rats with long-standing F344 RT produce antibodies against 
both glomerular and tubular basement membranes.38 
 Subsequently, antibodies directed against mesangial and 
endothelial cells have been detected in the sera of the 
allografts with long-standing RTs. Western blot analysis, 
followed by immunoprecipitation, has identified the anti-
body-binding sites on mesangial cells to be biglycan and 
decorin.39 It is recognized that both biglycan and decorin 
appear to play roles in the tissue repair process and bind 
transforming growth factor (TGF)-b, a profibrotic cytokine 
which may play a major role in CAN. Antibodies binding 
to biglycan and decorin appear to have the effect of gener-
ating more “free” TGF-b to interact with its receptors and 
interfere with the stimulation of matrix metalloproteases. 
TGF-b inhibits the proliferation of mesangial cells and may 
play a role in renal fibrosis by stimulating mesangial cells 
to produce matrix proteins. Fibroblasts are also stimulated 
by TGF-b to produce matrix protein.40
In CAN, the alteration of the extracellular matrix com-
partment and proliferation of various cell types are regulated 
by the metzincin superfamily of metallo-endopeptidases, 
including matrix metalloproteinases (MMPs), a disintegrin 
and metalloproteinase (ADAM) and meprin. Berthier et al41 
observed that members of metzincin families (MMP, ADAM, 
and meprin) and of tissue inhibitors of metalloproteinase 
(TIMPs) are differentially regulated in CAN in the F344-to-
LEW model. Messenger ribonucleic acid (mRNA) levels of 
MMPs (MMP-2/-11/-12/-14), their inhibitors (TIMP-1/-2), 
ADAM-17, and TGF-b1 significantly increase in CAN. 
In contrast, mRNA levels of MMP-9/-24 and meprin α/b 
downregulate significantly.41,42
International Journal of Nephrology and Renovascular Disease 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
317
Rat models of CAN
Cyclosporin
Diamond et al24 from Boston, USA, used cyclosporin 
(5 mg/kg/day) for the first 10 days post-RT to prevent acute 
rejection and studied the changes in renal function,  morphology, 
and immunohistology between F344-to-LEW allografts and 
LEW-to-LEW isografts over the course of 24 weeks. A higher 
urine albumin excretion was demonstrated in the allografts as 
early as 4 weeks after RT, which rose dramatically by 20 weeks. 
Serum creatinine was elevated in allografts after 16 weeks, while 
renal blood flow and glomerular filtration rate (GFR) measured 
by p-aminohippurate and inulin clearances, respectively, were 
significantly lower in the allografts at 24 weeks. The frequency 
of glomerulosclerotic lesions was significantly increased in 
allografts and correlated with albumin excretion. There was 
significantly greater infiltration of the glomeruli with cluster 
of differentiation (CD)8+ and pan-T-cells in the allografts.24 
Grenz et al43 demonstrated significant improvement in GFR 
in the same model when theophylline was given (10 mg/kg, 
subcutaneously) (GFR of allografts 0.23±0.05 mL/min/g kid-
ney weight [n=10] compared with 0.50±0.09 mL/min/g in rats 
receiving theophylline [n=9, P,0.01]) without affecting the 
interstitial infiltration of the graft by monocytes/macrophages 
and T-cells. Likewise, serum cytokines interleukin (IL)-2, 
IL-6, IL-10, tumor necrosis factor (TNF)-α, and erythro-
poietin plasma levels were not different among the allograft 
groups.43 In both studies, cyclosporin given for the first 
10 days prevented acute rejection and allowed development 
of CAN in the allografts.
Alloantibodies, cytokines,  
and adhesion molecules
Hancock et al44 from Boston examined the host immune 
mechanisms responsible for the initiation and progression of 
chronic rejection in the same model. Peak levels of immu-
noglobulin (Ig)M and IgG alloantibodies were demonstrated 
at 2–4 weeks by flow cytometry, with a gradual decline to 
baseline thereafter. Immunohistology showed early and 
progressive deposition of IgM, IgG, C3, and fibrin in the 
vessel walls and glomeruli. In addition, by 12 weeks, exten-
sive infiltration by activated IL-2 receptor positive (IL-2R+) 
macrophages and CD4+ T-cells could be demonstrated in the 
glomeruli and blood vessels, in conjunction with staining 
for cytokines such as TNF-α, IL-1, and IL-6. The persistent 
and dense intraglomerular expression of IL-6 indicated 
its potent mitogenic effect on mesangial cells leading to 
glomerulosclerosis.
There was also increased expression of intercellular adhe-
sion molecule-1 (ICAM-1) in the graft vascular endothelium, 
which peaked at 16 weeks and showed increased binding 
in vitro to naïve host lymphocytes.44 The authors concluded 
that an antibody-mediated host response followed by a 
cellular response was responsible for the release of cytokine 
production and upregulation of adhesion molecules which 
induced the scarring process leading to graft loss.
Prevention of chronic rejection
Manipulation of the cellular immune response
Several experiments have been carried out in the F344–LEW 
model to abrogate the alloantigen-driven histological and 
immunological events in order to delay or prevent  alloantigen 
recognition. T-cell activation requires two steps: namely, bind-
ing of T-cell receptor to the antigen presented by the antigen-
presenting cells (APCs) (signal 1) followed by  co-stimulation 
(signal 2) through binding of CD28  molecule of the T-cell 
to CD80 (B7-1) and CD86 (B7-2) on the APC. Blockade of 
the co-stimulation pathway (CD28–B7)  produces a state of 
anergy, a failure of T-cell activation, which is also produced 
by CD152 (cytotoxic T-lymphocyte antigen-4; CTLA-4) 
combined with CD28 and CD86.  Alternatively, CD40 ligand 
on T-cells can combine with CD40 on the APC to initiate the 
co-stimulation signal leading to activation of these cells.
Blockade of the co-stimulation pathway by the infusion 
of CTLA-4-immunoglobulin, which binds to B7 molecules 
on the surface of the APC, leads to significant reduction of 
proteinuria, glomerulosclerosis, intimal hyperplasia, and 
mononuclear cellular infiltration.45 Similarly, administration 
of an anti-CD28 monoclonal antibody significantly preserves 
graft morphology and recipient survival in this model by 
blocking the T-cell co-stimulation pathway.46
Blockade of chemokines
Chemokines are a family of small-size (8–10 kDa) chemotactic 
cytokines which, in transplantation, induce the recruitment 
and activation of T-cells and monocytes or macrophages. So 
far, more than 50 chemokines and 20 chemokine receptors 
have been identified. Members of the chemokine family are 
divided into four groups (C, CC, CXC, and CX3C) based 
upon the position of their first two cysteine residues. They are 
further classified as  inflammatory or hemostatic.
In F344-to-LEW rat allografts, BX-471, a chemokine 
receptor type 1 (CCR1) antagonist, prevents the infiltration 
of T-cells and macrophages, decreases cell proliferation 
(ED1, CD8, and Ki67), and reduces expression of acute 
phase reactive proinflammatory genes (heme oxygenase-1, 
 osteopontin) and molecules associated with f ibrosis 
 (plasminogen activator inhibitor-1, TGF-b, and biglycan). 
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There is a significantly lower number of smooth muscle 
actin-positive interstitial myofibroblasts and a reduction in 
the deposition of collagen.47
Similarly, Met-RANTES (Regulated on Activation, 
Normal T-cell Expressed), a chemokine receptor antagonist 
(CCR5), blocks the effects of RANTES in F344-to-LEW 
allografts, reducing the infiltration of lymphocytes and 
macrophages, accompanied by decreased mRNA expres-
sion of IL-2, IL-1b, TNF-α, and RANTES resulting in 
reduced glomerulosclerosis, tubulointerstitial fibrosis, and 
proteinuria.48
Immunosuppressive agents
Immunosuppressive drugs have reduced the incidence 
of acute rejection and improved graft survival. However, 
the majority are associated with side effects such as the 
nephrotoxicity of calcineurin inhibitors (CNIs), which 
are known to contribute to the development of CAN.49 
 Mycophenolate mofetil (MMF), in contrast, acts by inhibiting 
de novo DNA synthesis, cell surface molecule expression, 
and antibody production. MMF reduces CAN and improves 
allograft survival when given immediately or 8 weeks after 
RT.50 In the same model, Luo et al51 examined the effects of 
tacrolimus with MMF on renal fibrosis and observed progres-
sive deterioration of renal function and CAN  morphology 
in the vehicle and tacrolimus groups, while serum creati-
nine and inflammatory infiltration (Banff score) showed a 
significant decrease in the MMF group after 8 weeks post-
transplantation compared with those in the other groups. 
Furthermore, expression levels of connective tissue growth 
factor and α-smooth muscle actin in the MMF group were 
significantly reduced, and the downregulated expression of 
E-cadherin was abated.51
Sirolimus and its derivative, everolimus, significantly 
reduce infiltration of the allograft with macrophages and 
lymphocytes and reduce expression of TGF-b, ICAM-1, 
and VCAM (vascular cell adhesion molecule)-1, reducing 
interstitial fibrosis and tubular atrophy (TA) and prolonging 
allograft survival.52–54
Ko et al,55 in the same model, observed greater 
protection against vasculopathy in the sirolimus-treated 
group, but sirolimus induced proteinuria. The effects were 
likely to be related to inhibition of vascular endothelial 
growth factor signaling.55 In the same model, Luo et al51 
concluded that sirolimus ameliorated fibrogenesis in kid-
ney allografts by inhibiting the epithelial mesenchymal 
transition (EMT) process, whereas cyclosporine did not 
have this effect.
Oxidative stress
Oxidative stress is increased in the F344–LEW rat trans-
plant model and is associated with EMT and chronic 
 interstitial fibrosis. Nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase (Nox) is an important source of 
reactive oxygen species generation in the kidney. Inhibition 
of NADPH-2 (Nox-2) by diphenyleneiodonium or apocynin 
reduces fibronectin and phosphor-Smad2 and increases 
E-cadherin levels, thereby inhibiting EMT and fibrogenesis.56 
In the same model, L-arginine decreases proteinuria and 
glomerulosclerosis.57 However, vitamin E supplementation 
alone does not prevent CAN.58 Both in human RT recipients 
and in F344-to-LEW allografts, MMF significantly down-
regulates Nox-2 activation and EMT through the nuclear 
factor-κB pathway in tubular epithelial cells.59
Angiotensin antagonists
Angiotensin II increases the expression of cytokines and 
adhesion molecules thereby stimulating the synthesis of extra-
cellular matrix and increasing glomerular capillary  pressure. 
Administration of an angiotensin converting enzyme inhibitor 
(trandolapril) or angiotensin II receptor blocker (losartan) 
in this model leads to diminished expression of chemokine 
MCP-1 (monocyte chemoattractant protein-1), preserva-
tion of glomerular and tubulointerstitial structures, reduced 
proteinuria, and improved graft survival.60,61 Combination of 
losartan and MMF completely prevents the development of 
proteinuria, largely reduces glomerular and tubulointerstitial 
injury, and suppresses intragraft cell infiltration, thereby 
producing a better outcome in comparison with transplants 
receiving a single agent.50
Lipid lowering agents
In the F344-to-LEW renal allograft model, pravastatin 
reduces macrophage and T-cell graft infiltration and decreases 
intragraft expression of TGF-b, causing an attenuation of the 
recipient anti-donor IgG alloantibodies and upregulation of 
the anti-apoptotic gene Bag-1.62
Mineralocorticoid receptor antagonist agent
The mineralocorticoid hormone aldosterone is involved 
in development and/or progression of renal diseases via 
 interaction with a non-epithelial mineralocorticoid receptor 
(eg, reducing neointima formation). Lahmer et al63 examined 
the effects of the aldosterone synthase inhibitor fadrozole 
and the mineralocorticoid receptor antagonist  spironolactone 
compared with vehicle in the F344-to-LEW rat model 
of CAN. Fadrozole- and spironolactone-treated animals 
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demonstrated a higher degree of proteinuria, pathologically 
elevated potassium values, higher tubulointerstitial  damage 
and glomerulosclerosis, and markedly increased heart 
weight/bodyweight as compared with vehicle. The positive 
effects of inhibition of aldosterone as described in cardiac 
models could not be detected in kidney recipients.63
DA-to-BN model of CAN
DA-to-BN rat model, which requires triple immunosuppression 
with cyclosporin (5 mg/kg/day), azathioprine (2 mg/kg/day), 
and methylprednisolone (2 mg/kg/day), has been extensively 
studied by Soots et al.23 This model developed an early acute 
rejection 5–7 days after RT and chronic rejection within 
40–60 days after RT, with chronic allograft damage index 
(CADI) score of 7.9±3.1 compared with syngenic transplants, 
which showed no evidence of acute or chronic rejection 
(CADI: 1.7±2.0). In the same study, combinations of other 
strains of rats such as DA-to-albino Oxford and piebald-
viral-Glaxo (PVG)-to-BN were examined. The DA-to-albino 
Oxford combination demonstrated a prolonged acute rejec-
tion, but no characteristic chronic changes. The PVG-to-BN 
combination did not show changes of either acute or chronic 
rejection. The grafts were monitored with ultrasound-guided 
fine-needle aspiration cytology. This study concluded that the 
experimental model of DA-to-BN of RT resembles the CAN 
seen in human clinical RT.23
The same authors have used the DA-to-BN model to 
demonstrate a significant rise in the collagen/DNA ratio 
in cytomegalovirus (CMV)-infected grafts compared with 
uninfected animals, correlating with the development of 
fibrosis. The expression of type I and III collagen mRNA and 
presence of myofibroblasts was associated with interstitial 
fibrosis in CMV-infected grafts. It was concluded that CMV 
accelerated both atherosclerosis and the development of CAN 
in rat allograft kidneys.64,65 Soots et al66 examined the effect 
of flushing the donor kidney with Euro-Collins® solution 
(Fresenius Aktiengesellschaft, Oberursel, Germany) contain-
ing sodium nitroprusside solution in this model and observed 
significant reduction in CADI score of TA and interstitial 
fibrosis with the use of sodium nitroprusside.66
DA-to-WF model of CAN
Yilmaz et al67 studied chronic rejection in the DA-to-WF 
where the allografts, given cyclosporin (5 mg/kg/day, 
subcutaneously) for 1 week, developed chronic rejec-
tion 3 months post-transplantation. Allografts receiving 
cyclosporin (5 mg/kg/day, subcutaneously) for 12 weeks 
did not show changes of chronic rejection. In this model, 
prolonged use of cyclosporin prevented the development of 
acute  rejection. Syngenic DA-to-DA RTs did not show any 
evidence of chronic rejection.67,68 Savikko et al69  investigated 
the role of platelet-derived growth factor (PDGF) in 
the same model and demonstrated that administration of the 
imanitib (10 mg/kg/day, orally), a PDGF inhibitor, for the 
first 30 days after RT completely prevented development of 
CAN at 90 days in the treated group. An immunosuppressive 
drug, FK778, inhibits de novo pyrimidine biosynthesis and 
several receptor tyrosine kinases. Rintala et al70 investigated 
its effects on acute and chronic rejection as well as post-
 transplant PDGF and TGF-b expression in  combination 
therapy with CNIs. FK778 in combination with CNIs 
significantly reduced both early and late PDGF and TGF-b 
expression and development of CAN.
DA-to-LEW model of CAN
Pascher et al31 have described the development of CAN 
using DA rats as donors to LEW recipients in a variety of 
immune-modulating models. One model, considered to 
be a high-responder immunologically, was used in experi-
ments which involved the use of carbon monoxide to reduce 
immunogenicity and thereby the development of CAN.71 
Transplanting kidneys from DA to LEW rats, without immu-
nosuppression, leads to death of rats from acute  rejection 
some 7 days after transplantation.72 Denecke et al11 had 
examined the effect of low-dose cyclosporine in the same 
model and observed induction of donor  hypo-responsiveness 
to secondary renal allografts, significantly reduced alloan-
tibody titers in the primary recipients, and dose-dependent 
and transferable “pro-tolerogenic” effect of low-dose 
cyclosporine treatment.11
SD-to-WF model of CAN
The SD-to-WF combination is an accelerated model of 
CAN, where histological evidence of CAN appears as early 
as 4 weeks post-RT. Teng et al73 examined the expression of 
the cytoprotective genes A20, heme oxygenase (HO)-1, Bcl-2, 
and Bcl-XL in this model using three different immunosup-
pressive regimens. All animals received cyclosporin 10 mg/
kg/day for 10 days, but two further groups were maintained 
on either cyclosporin 6 mg/kg/day or MMF 20 mg/kg/day. 
At the end of 8 weeks, CAN was evident in all groups, but 
the expression of A20 in grafted kidneys was significantly 
higher in the MMF than in the cyclosporine group, helping to 
explain the mechanism by which MMF ameliorates transplant 
arteriosclerosis in experimental chronic rejection. There was 
no significant difference between the cyclosporin and the 
International Journal of Nephrology and Renovascular Disease 2014:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
320
Shrestha and Haylor
MMF groups in the expression of HO-1, Bcl-2, and Bcl-XL.73 
Similar results were observed when rapamycin was compared 
with tacrolimus in this model.74
Fractalkine is a unique chemokine that functions both as 
a potent chemoattractant molecule (soluble form)1 and as 
an adhesion molecule (membrane anchored form) for cells 
expressing the fractalkine receptor CX3CR1, such as mono-
cytes, NK (natural killer) cells, and subsets of CD8+ T-cells, 
involved in chronic transplant arteriosclerosis. Cao et al32 
demonstrated increased expression of the fractalkine recep-
tor CX3CR1 in the SD-to-WF model of RT. Fractalkine/
CX3CR1 was mostly expressed in the tubulointerstitium 
and tubular epithelial cell basolateral membrane. A propor-
tion of the vessel showed positive staining for fractalkine/
CX3CR1, occasionally in glomerular parietal wall cells, 
was significantly lower in MMF than cyclosporine-treated 
animals.32
LEW-to-BN model of CAN
Transplanting kidneys from LEW-to-B (RT1n) rats shows inter-
stitial mononuclear cell infiltration, tubulitis, and glomerulitis, 
in addition to early phase of arteritis at 30 days. By 80 days, 
TA is seen in 25%–50% and interstitial fibrosis in up to 25% 
of renal cortex. There is focal, diffuse,  segmental, or globular 
glomerulosclerosis. In a study by Neto et al,33 all recipients had 
received tacrolimus (0.5 mg/kg/day) for 7 days.  Cardinal et al75 
demonstrated that the administration of molecular hydrogen 
dissolved in water to this model slowed the progression of CAN, 
reduced oxidant injury and inflammatory mediator produc-
tion, and improved overall survival. Inflammatory signaling 
pathways, such as mitogen-activated protein kinases, were less 
activated in renal allografts from hydrogen water-treated rats 
as compared with regular water-treated rats.75
WF-to-LEW model of CAN
Solini et al76 developed a model of CAN using a fully 
MHC-mismatched rat strain combination, with WF rats as 
kidney donor and LEW rats as recipients. The two strains 
 differ for class I, class II, and non-MHC genes. Cyclosporin 
(5 mg/kg/ day, intramuscularly) needed to be given for the first 
10 days to  prevent acute rejection. At 120 days, the allografts 
developed features of CAN and donor-specific antibodies and 
chronic antibody-mediated rejection.76 A few studies have 
been carried out in this model, which include gene transfer of 
CTLA-4 Ig into donor kidney, leading to prevention of pro-
gressive proteinuria and CAN, and transfer of donor-specific 
T helper-2 clones into recipient rats to regulate alloimmune 
response and prevention of CAN.77,78
Conclusion
We reviewed the relevant published literature that described 
RT in rat models of CAN employing combinations of strains 
and the outcomes of various interventions. We believe that 
the review will help researchers to understand the applica-
tion of various rat models of CAN in understanding the 
molecular mechanisms and development of novel treatments 
for CAN.
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